CWM Advisors LLC lessened its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 8.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 14,208 shares of the company’s stock after selling 1,230 shares during the period. CWM Advisors LLC’s holdings in Aerie Pharmaceuticals were worth $254,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. Morgens Waterfall Vintiadis & Co. Inc. purchased a new position in Aerie Pharmaceuticals during the fourth quarter valued at approximately $1,081,000. Russell Investments Group Ltd. grew its stake in shares of Aerie Pharmaceuticals by 115.2% during the 4th quarter. Russell Investments Group Ltd. now owns 103,462 shares of the company’s stock worth $1,397,000 after purchasing an additional 55,387 shares during the period. Global Retirement Partners LLC increased its holdings in shares of Aerie Pharmaceuticals by 101.5% during the 1st quarter. Global Retirement Partners LLC now owns 1,666 shares of the company’s stock valued at $30,000 after purchasing an additional 839 shares in the last quarter. William Blair Investment Management LLC lifted its stake in shares of Aerie Pharmaceuticals by 6.5% in the 4th quarter. William Blair Investment Management LLC now owns 1,512,041 shares of the company’s stock valued at $20,428,000 after purchasing an additional 92,359 shares during the period. Finally, State of Wisconsin Investment Board boosted its holdings in Aerie Pharmaceuticals by 142.9% during the fourth quarter. State of Wisconsin Investment Board now owns 143,058 shares of the company’s stock worth $1,933,000 after buying an additional 84,158 shares in the last quarter. Hedge funds and other institutional investors own 99.89% of the company’s stock.
Shares of AERI opened at $17.41 on Friday. The stock has a 50 day moving average price of $17.70 and a 200 day moving average price of $15.69. Aerie Pharmaceuticals, Inc. has a one year low of $9.01 and a one year high of $21.30. The company has a debt-to-equity ratio of 3.41, a quick ratio of 3.10 and a current ratio of 3.33. The stock has a market capitalization of $816.41 million, a price-to-earnings ratio of -4.16 and a beta of 0.79.
A number of research analysts have weighed in on AERI shares. HC Wainwright reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, March 1st. Needham & Company LLC assumed coverage on Aerie Pharmaceuticals in a report on Friday, April 30th. They issued a “buy” rating and a $26.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $22.78.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma.
Recommended Story: What are gap-up stocks?
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.